Unknown

Dataset Information

0

Congenital myopathy-causing tropomyosin mutations induce thin filament dysfunction via distinct physiological mechanisms.


ABSTRACT: In humans, congenital myopathy-linked tropomyosin mutations lead to skeletal muscle dysfunction, but the cellular and molecular mechanisms underlying such dysfunction remain obscure. Recent studies have suggested a unifying mechanism by which tropomyosin mutations partially inhibit thin filament activation and prevent proper formation and cycling of myosin cross-bridges, inducing force deficits at the fiber and whole-muscle levels. Here, we aimed to verify this mechanism using single membrane-permeabilized fibers from patients with three tropomyosin mutations (TPM2-null, TPM3-R167H and TPM2-E181K) and measuring a broad range of parameters. Interestingly, we identified two divergent, mutation-specific pathophysiological mechanisms. (i) The TPM2-null and TPM3-R167H mutations both decreased cooperative thin filament activation in combination with reductions in the myosin cross-bridge number and force production. The TPM3-R167H mutation also induced a concomitant reduction in thin filament length. (ii) In contrast, the TPM2-E181K mutation increased thin filament activation, cross-bridge binding and force generation. In the former mechanism, modulating thin filament activation by administering troponin activators (CK-1909178 and EMD 57033) to single membrane-permeabilized fibers carrying tropomyosin mutations rescued the thin filament activation defect associated with the pathophysiology. Therefore, administration of troponin activators may constitute a promising therapeutic approach in the future.

SUBMITTER: Ochala J 

PROVIDER: S-EPMC3459469 | biostudies-literature | 2012 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Congenital myopathy-causing tropomyosin mutations induce thin filament dysfunction via distinct physiological mechanisms.

Ochala Julien J   Gokhin David S DS   Pénisson-Besnier Isabelle I   Quijano-Roy Susana S   Monnier Nicole N   Lunardi Joël J   Romero Norma B NB   Fowler Velia M VM  

Human molecular genetics 20120713 20


In humans, congenital myopathy-linked tropomyosin mutations lead to skeletal muscle dysfunction, but the cellular and molecular mechanisms underlying such dysfunction remain obscure. Recent studies have suggested a unifying mechanism by which tropomyosin mutations partially inhibit thin filament activation and prevent proper formation and cycling of myosin cross-bridges, inducing force deficits at the fiber and whole-muscle levels. Here, we aimed to verify this mechanism using single membrane-pe  ...[more]

Similar Datasets

| S-EPMC4347224 | biostudies-literature
| S-EPMC2906900 | biostudies-other
| S-EPMC4911820 | biostudies-literature
| S-EPMC7109180 | biostudies-literature
| S-EPMC4109545 | biostudies-literature
| S-EPMC5768522 | biostudies-literature
| S-EPMC5344678 | biostudies-literature
| S-EPMC1301196 | biostudies-other
| S-EPMC4621613 | biostudies-literature
| S-EPMC10227645 | biostudies-literature